Latest News
UK medicines assessor NICE (National Institute for Health and Care Excellence) has just recommended another combination of drugs for women with advanced hormone-receptor-positive breast cancer. Ribociclib is one of three drugs in the CDK 4/6 inhibitor class, which can extend and improve the lives of women with this type of breast cancer. Ribociclib has been publicly funded in the UK since late 2017, and can now be used with an anti-oestrogen drug called fulvestrant. Clinical trials have shown that this combination could be more effective than ribociclib alone.
Three Cambridge women are using their breast cancer journeys to bring support and reassurance to others.
Local women Ruth Crampton, Carillon Faery and Mandy Robinson have partnered with national charity Breast Cancer Support (BCS) to set up a support group for women diagnosed with breast cancer. Breast Cancer Support Cambridge will provide peer support from the positive, personal perspective of those who have ‘been there too.’
Come join us! The Busting with Life Dragon Boat Team
Have you or someone you know had breast cancer and want to try something new?
Come and give dragon boating a go!
It's fun, great for fitness and proven to be beneficial for breast cancer survivors. Become part of a team of women who participate in this great sport while having a lot of fun!
The Busting with Life team is looking for new recruits so please call Vicki on 021 038 2581 or Marion on 027 256 5827
Email: info@bustingwithlife.co.nz
Check out Busting with Life at www.bustingwithlife.org.nz
4 July 2019
Progress continues to be made through world-leading research to identify which treatments will work best for different sub-types of breast cancer.
Breast Cancer Aotearoa Coalition (BCAC) is 100% behind Blair Vining’s petition to Parliament calling for a national cancer agency to address New Zealand’s cancer death rates.
Click here to sign the petition: Petition of Blair Vining: Better cancer care for all New Zealanders, stewarded by a National Cancer Agency
Malaghan Institute media release
The Malaghan Institute’s ambitious plans to establish a platform for CAR T-cell cancer therapy has got the backing from the New Zealand government in a funding deal announced today.
In brilliant news, it has been discovered that adding ribociclib to first-line endocrine therapy significantly improves both progression free and overall survival (PFS and OS) for premenopausal women with advanced breast cancer.
The Waikato Breast Cancer Research Trust (WBCRT) is seeking participants with moderately severe treatment-resistant lymphoedema for this research. Is lymphoedema of your arm an ongoing problem for you? Have you undergone at least three months of lymphoedema therapy? If so, you may be eligible for this trial.
Key findings announced at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago include breakthroughs in the treatment of breast cancer and research. In a series of articles including this one, we outline some of the exciting developments reported.
Women who give so much to their families and communities now need help from the community to contribute to funding the medicines they need to treat their advanced breast cancer. These medicines help extend lives and improve quality of life. They are listed in international guidelines as the treatments that should be provided and they are funded across the developed world, but they are not funded in New Zealand.
